Disclosed herein are methods of treating and making prognostic prediction of, monitoring of therapeutic outcome for treatment of cervical carcinoma in a patient in need thereof by quantifying gene expression in a sample, wherein the genes include 10 high risk genes; calculating the subject's survival risk score by determining the protein expression levels and their relationships using machine learning (ML) and artificial intelligence. The survival risk category of a patient is determined by the consensus or plurality voting of a large number of ML models that individually have excellent predictive potential, thus providing a very robust prognostic biomarker for cervical carcinoma.

Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed. Also disclosed is the use of IP-10 as a biomarker for predicting treatment efficacy.

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

The present disclosure relates to antibodies, for example monoclonal antibodies, and their use in clinical patient evaluation and therapy. The present disclosure further relates to a method for modulating the activity of human CXCL-1 protein (hereinafter, referred to as CXCL1). In an aspect, antibodies described herein are capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis and inflammatory diseases.

The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with patho-logical angiogenesis.

Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.

The invention generally features compositions and methods for the diagnosis, treatment, and monitoring of neoplasia in a subject, as well as methods of treatment selection.

Described are mutant Platelet Factor 4 (PF4) proteins that exhibit different binding affinities to vaccine induced immune thrombotic thrombocytopenia (VITT) antibodies or non-heparin-induced thrombocytopenia (non-HIT) antibodies relative to heparin-induced thrombocytopenia (HIT) antibodies. Also provided herein are methods for differentiating between VITT, HIT, and/or non-HIT in subjects suspected of having VITT, HIT, or non-HIT.

Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.

The present invention relates to methods for detecting, diagnosing and/or treating ulcerative interstitial cystitis (UIC) by detecting in a urine sample from a patient the levels of each of the proteins IL-6, IL-8 and GRO [also known as CXCL 1 (chemokine C-X-C motif ligand 1]. In some embodiments, the method also includes diagnosing the patient with UIC when each of the proteins IL-6, IL-8 and GRO in the urine sample is at a different level than a statistically validated threshold for the respective proteins. In some embodiments a companion diagnostic, e.g., a cystoscopy, is used in conjunction with the protein biomarker diagnostic. In some embodiments, once UIC is diagnosed, the patient is treated for the UIC.